Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 Operating Margin % is 0.00% as of Jun. 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, SILO Pharma ranks worse than 92.92% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. SILO Pharma's Operating Income for the
three
months ended in Jun. 2026 was $-0.93 Mil. SILO Pharma's Revenue for the
three
months ended in Jun. 2026 was $0.00 Mil. Therefore, SILO Pharma's Operating Margin % for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for SILO Pharma's Operating Margin % or its related term are showing as below:
SILO'
s Operating Margin % Range Over the Past 10 Years
Min: -8262.96 Med: -5211.12 Max: -2229.27
Current: -8262.96
SILO's Operating Margin % is ranked worse than 92.92% of 946
companies
in the Biotechnology industry
Industry Median: -80.89
vs SILO: -8262.96
SILO Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
SILO Pharma's Operating Income for the
three
months ended in Jun. 2026 was $-0.93 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.46 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
SILO Pharma Operating Margin % Related Terms
SILO Pharma Operating Margin % Historical Data
* Premium members only.
The historical data trend for SILO Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO vs ELAB, GLMD, APVO: Operating Margin % Comparison
For the Biotechnology subindustry, SILO Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
SILO Pharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a Operating Margin % of 0.00% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on SILO Pharma and its competitors. According to the industry distribution chart, SILO Pharma ranks #879 out of 946 companies in the Biotechnology industry, placing it in the top 92.9%.
Is SILO Pharma's Operating Margin % too high?
SILO Pharma's current Operating Margin % is 0.00%. Based on the distribution chart, SILO Pharma ranks #879 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Operating Margin % compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #879 out of 946 companies for Operating Margin %. This places SILO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on SILO Pharma and its competitors. SILO Pharma's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Operating Margin % is 0.00%. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For SILO Pharma (SILO), the current Operating Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
Operating Margin %: 0.00%
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
